Unknown

Dataset Information

0

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.


ABSTRACT: The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90 mg/m(2) fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n = 44) or FLU/TBI (n = 41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P = .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P = .06), relapse-related mortality (37% versus 28%; HR, .53; P = .09), and a lower progression-free survival (36% versus 53%; HR, .56; P = .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P < .0001) and 84 (68% versus 92%; P < .0001), as was NK cell chimerism on day 28 (75% versus 96%; P = .0005). In conclusion, this randomized trial demonstrates the importance of fludarabine in augmenting the graft-versus-tumor effect by ensuring prompt and durable high-level donor engraftment early after transplantation.

SUBMITTER: Kornblit B 

PROVIDER: S-EPMC3755028 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

Kornblit Brian B   Maloney David G DG   Storb Rainer R   Storek Jan J   Hari Parameswaran P   Vucinic Vladan V   Maziarz Richard T RT   Chauncey Thomas R TR   Pulsipher Michael A MA   Bruno Benedetto B   Petersen Finn B FB   Bethge Wolfgang A WA   Hübel Kai K   Bouvier Michelle E ME   Fukuda Takahiro T   Storer Barry E BE   Sandmaier Brenda M BM  

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20130611 9


The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90 mg/m(2) fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n = 44) or FLU/TBI (n = 41). All patients ha  ...[more]

Similar Datasets

| S-EPMC4332717 | biostudies-literature
| S-EPMC3673760 | biostudies-literature
| S-EPMC2662650 | biostudies-literature
| S-EPMC7515850 | biostudies-literature
| S-EPMC8343993 | biostudies-literature
| S-EPMC10837477 | biostudies-literature
| S-EPMC3996925 | biostudies-literature
| S-EPMC10916301 | biostudies-literature
| S-EPMC7319212 | biostudies-literature
| S-EPMC5876349 | biostudies-literature